Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 3 | 0 | 0 | 0 | 0 |
Analyst Firms Making Recommendations1
- EF Hutton
- HC Wainwright & Co.
- Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Acasti Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/15/2023 | ACST | Buy Now | Acasti Pharma | $2.31 | 8.22% | EF Hutton | Constantine Davides | → $15 | Reiterates | → Buy | Get Alert |
| 12/19/2022 | ACST | Buy Now | Acasti Pharma | $2.31 | 8.22% | EF Hutton | Constantine Davides | → $15 | Initiates | → Buy | Get Alert |
| 12/15/2022 | ACST | Buy Now | Acasti Pharma | $2.31 | 3.89% | HC Wainwright & Co. | Oren Livnat | → $14.4 | Initiates | → Buy | Get Alert |
| 12/22/2021 | ACST | Buy Now | Acasti Pharma | $2.31 | 159.72% | Oppenheimer | Leland Gershell | → $36 | Initiates | → Outperform | Get Alert |
| 12/21/2021 | ACST | Buy Now | Acasti Pharma | $2.31 | 159.72% | Oppenheimer | Leland Gershell | → $36 | Initiates | → Outperform | Get Alert |
What is the target price for Acasti Pharma (ACST)?
The latest price target for Acasti Pharma (NASDAQ: ACST) was reported by EF Hutton on February 15, 2023. The analyst firm set a price target for $2.50 expecting ACST to rise to within 12 months (a possible 8.22% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acasti Pharma (ACST)?
The latest analyst rating for Acasti Pharma (NASDAQ: ACST) was provided by EF Hutton, and Acasti Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Acasti Pharma (ACST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acasti Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acasti Pharma was filed on February 15, 2023 so you should expect the next rating to be made available sometime around February 15, 2024.
Is the Analyst Rating Acasti Pharma (ACST) correct?
While ratings are subjective and will change, the latest Acasti Pharma (ACST) rating was a reiterated with a price target of $0.00 to $2.50. The current price Acasti Pharma (ACST) is trading at is $2.31, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.